MA47331A - Compositions et procédés pour la déplétion des cellules cd137+ - Google Patents

Compositions et procédés pour la déplétion des cellules cd137+

Info

Publication number
MA47331A
MA47331A MA047331A MA47331A MA47331A MA 47331 A MA47331 A MA 47331A MA 047331 A MA047331 A MA 047331A MA 47331 A MA47331 A MA 47331A MA 47331 A MA47331 A MA 47331A
Authority
MA
Morocco
Prior art keywords
deletion
compositions
cells
methods
Prior art date
Application number
MA047331A
Other languages
English (en)
Inventor
Anthony Boitano
Michael Cooke
Adam Hartigan
Megan D Hoban
Rahul Palchaudhuri
Original Assignee
Magenta Therapeutics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Magenta Therapeutics Inc filed Critical Magenta Therapeutics Inc
Publication of MA47331A publication Critical patent/MA47331A/fr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/28—Bone marrow; Haematopoietic stem cells; Mesenchymal stem cells of any origin, e.g. adipose-derived stem cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/08—Peptides having 5 to 11 amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6801—Drug-antibody or immunoglobulin conjugates defined by the pharmacologically or therapeutically active agent
    • A61K47/6803—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates
    • A61K47/6811—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates the drug being a protein or peptide, e.g. transferrin or bleomycin
    • A61K47/6817—Toxins
    • A61K47/6831—Fungal toxins, e.g. alpha sarcine, mitogillin, zinniol or restrictocin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
    • A61K47/6849—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a receptor, a cell surface antigen or a cell surface determinant
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2878—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the NGF-receptor/TNF-receptor superfamily, e.g. CD27, CD30, CD40, CD95
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/57—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2
    • A61K2039/572—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2 cytotoxic response
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C07K2317/732—Antibody-dependent cellular cytotoxicity [ADCC]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Immunology (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Toxicology (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Cell Biology (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Transplantation (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Developmental Biology & Embryology (AREA)
  • Biomedical Technology (AREA)
  • Hematology (AREA)
  • Biotechnology (AREA)
  • Virology (AREA)
  • Zoology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
MA047331A 2017-01-20 2018-01-19 Compositions et procédés pour la déplétion des cellules cd137+ MA47331A (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201762448741P 2017-01-20 2017-01-20
US201762595977P 2017-12-07 2017-12-07

Publications (1)

Publication Number Publication Date
MA47331A true MA47331A (fr) 2019-11-27

Family

ID=62907802

Family Applications (1)

Application Number Title Priority Date Filing Date
MA047331A MA47331A (fr) 2017-01-20 2018-01-19 Compositions et procédés pour la déplétion des cellules cd137+

Country Status (13)

Country Link
US (3) US10576161B2 (fr)
EP (1) EP3571230A4 (fr)
JP (2) JP7256744B2 (fr)
KR (2) KR20240161216A (fr)
CN (1) CN110461876B (fr)
AU (1) AU2018209452B2 (fr)
BR (1) BR112019014991A2 (fr)
IL (1) IL268058B2 (fr)
MA (1) MA47331A (fr)
MX (2) MX395639B (fr)
SG (2) SG10202102897PA (fr)
TW (1) TWI825007B (fr)
WO (1) WO2018134787A2 (fr)

Families Citing this family (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BR112018076263A2 (pt) 2016-06-17 2019-03-26 Magenta Therapeutics, Inc. composições e métodos para a depleção de células
WO2018134787A2 (fr) * 2017-01-20 2018-07-26 Magenta Therapeutics, Inc. Compositions et procédés pour la déplétion des cellules cd137+
CN119857155A (zh) 2017-11-29 2025-04-22 海德堡医药研究有限责任公司 用于耗尽cd5+细胞的组合物和方法
JP7642531B2 (ja) 2018-05-11 2025-03-10 ビーム セラピューティクス インク． プログラム可能塩基エディターシステムを用いて病原性アミノ酸を置換する方法
WO2020023561A1 (fr) * 2018-07-23 2020-01-30 Magenta Therapeutics, Inc. Utilisation d'un conjugué anticorps anti-cd5 -médicament (adc) dans une thérapie cellulaire allogénique
CN112739341A (zh) * 2018-07-23 2021-04-30 美真达治疗公司 抗cd2抗体药物缀合物(adc)在同种异体细胞疗法中的用途
CA3107019A1 (fr) 2018-07-23 2020-01-30 Magenta Therapeutics, Inc. Utilisation d'un conjugue anticorps-medicament anti-cd137 dans une therapie cellulaire allogenique
CA3128755C (fr) 2019-02-13 2024-06-04 Beam Therapeutics Inc. Compositions et methodes de traitement d'hemoglobinopathies
SG11202110287QA (en) 2019-04-24 2021-10-28 Heidelberg Pharma Res Gmbh Amatoxin antibody-drug conjugates and uses thereof
EP3966252A4 (fr) * 2019-05-10 2023-01-25 Lyvgen Biopharma Holdings Limited Anticorps anti-cd137 humanisés et leurs utilisations
AU2020286508A1 (en) * 2019-06-05 2022-01-06 Heidelberg Pharma Research Gmbh T-cell depleting therapies
CN114630904B (zh) * 2019-08-29 2025-04-08 比姆医疗股份有限公司 用于无毒调理的组合物和方法
PH12022553153A1 (en) 2020-05-19 2024-02-26 Boehringer Ingelheim Int Binding molecules for the treatment of cancer
US20230242658A1 (en) * 2020-06-30 2023-08-03 Nona Biosciences (Suzhou) Co., Ltd. 4-1bb-binding protein and use thereof
CN114752563A (zh) * 2020-12-28 2022-07-15 广州辑因医疗科技有限公司 用于扩增并维持HSCs自我更新能力和分化潜能的培养基组合物及其应用
JP2024512478A (ja) 2021-03-19 2024-03-19 ハイデルベルク ファルマ リサーチ ゲゼルシャフト ミット ベシュレンクテル ハフツング Ｂリンパ球特異的アマトキシン抗体コンジュゲート
CN114369581B (zh) * 2021-12-30 2023-10-20 杭州医学院 一种具有抗肿瘤免疫功能重组腺病毒、制备方法及应用
WO2025128002A1 (fr) * 2023-12-15 2025-06-19 National University Of Singapore Anticorps anti-cd137 et son utilisation

Family Cites Families (166)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6074650A (en) 1985-06-24 2000-06-13 Hoechst Aktiengesellschaft Membrane anchor/active compound conjugate, its preparation and its uses
US5451575A (en) 1988-02-19 1995-09-19 J. W. Broadbent Nominees Pty., Ltd. Method of treating liver dysfunction with 24-R scymnol
US6303121B1 (en) 1992-07-30 2001-10-16 Advanced Research And Technology Method of using human receptor protein 4-1BB
US6355476B1 (en) 1988-11-07 2002-03-12 Advanced Research And Technologyinc Nucleic acid encoding MIP-1α Lymphokine
US6362325B1 (en) 1988-11-07 2002-03-26 Advanced Research And Technology Institute, Inc. Murine 4-1BB gene
US5786457A (en) 1989-02-23 1998-07-28 Colorado State University Research Foundation Hormone-nuclease compounds and method for regulating hormone related diseases
WO1990009799A1 (fr) 1989-02-23 1990-09-07 Colorado State University Research Foundation ANALOGUES DE GnRH DETRUISANT LES GONADOTROPES
US5273738A (en) 1990-03-03 1993-12-28 Fred Hutchinson Cancer Research Center Radiation delivery to lymphoid and marrow tissues
US5367057A (en) 1991-04-02 1994-11-22 The Trustees Of Princeton University Tyrosine kinase receptor flk-2 and fragments thereof
ATE169031T1 (de) 1991-04-05 1998-08-15 Univ Washington Zellrezeptor spezifische monoklonale antikörper gegen stammzell-faktor-rezeptor
AU3665293A (en) 1992-02-14 1993-09-03 Merck & Co., Inc. Chimeric toxins binding to the GnRH receptor
WO1994025621A1 (fr) 1993-04-30 1994-11-10 Lxr Biotechnology Inc. Procedes d'identification d'agents ayant une efficacite therapeutique potentielle et souches cellulaires a utiliser dans lesdits procedes
US5674704A (en) 1993-05-07 1997-10-07 Immunex Corporation Cytokine designated 4-IBB ligand
US7211259B1 (en) 1993-05-07 2007-05-01 Immunex Corporation 4-1BB polypeptides and DNA encoding 4-1BB polypeptides
US7138500B1 (en) 1993-05-07 2006-11-21 Immunex Corporation Antibodies to human 4-1BB
US6214345B1 (en) 1993-05-14 2001-04-10 Bristol-Myers Squibb Co. Lysosomal enzyme-cleavable antitumor drug conjugates
US6024957A (en) 1993-06-02 2000-02-15 Research Corporation Technologies, Inc. Immunomodulators and methods for the prevention and reversal of organ transplant rejection using same
US6106834A (en) 1993-06-02 2000-08-22 Research Corporation Technologies, Inc. Use of anti-CD45 leukocyte antigen antibodies for immunomodulation
AU697482B2 (en) 1993-09-16 1998-10-08 Indiana University Research And Technology Corporation Human receptor H4-1BB
GB9323199D0 (en) 1993-11-10 1994-01-05 Falkenberg J H F Leukaemia treatment
US5635388A (en) 1994-04-04 1997-06-03 Genentech, Inc. Agonist antibodies against the flk2/flt3 receptor and uses thereof
AU5369996A (en) 1995-03-23 1996-10-08 Indiana University Foundation Monoclonal antibody against human receptor protein 4-1bb and methods of its use for treatment of diseases
DK0766745T3 (da) 1995-04-08 2002-11-25 Lg Chemical Ltd Monoklonalt antistof, som er specifikt for humant 4-1BB samt cellelinje, som producerer dette
DE19600589C1 (de) 1996-01-10 1997-01-16 Univ Eberhard Karls Antikörper A3C6E2
DE19608769C1 (de) 1996-03-07 1997-04-10 Univ Eberhard Karls Antikörper BV10A4H2
US5874240A (en) 1996-03-15 1999-02-23 Human Genome Sciences, Inc. Human 4-1BB receptor splicing variant
KR100520339B1 (ko) 1996-10-11 2005-10-12 브리스톨-마이어스스퀴브컴파니 면역조절 방법 및 조성물
US6759509B1 (en) 1996-11-05 2004-07-06 Bristol-Myers Squibb Company Branched peptide linkers
JP2001521520A (ja) 1997-04-11 2001-11-06 ジー．ディー．サール アンド カンパニー 抗α▲下ｖ▼β▲下３▼インテグリン抗体アンタゴニスト
DE19727814C1 (de) 1997-06-30 1998-10-01 Univ Eberhard Karls Anitkörper 4G8B4B12
US20030096976A1 (en) 1998-11-17 2003-05-22 Hong Hyo Jeong Humanized antibodies LB-00503 and LB-00506 specific for human 4-1BB and pharmaceutical compositions comprising said humanized antibodies
KR20000034847A (ko) 1998-11-17 2000-06-26 성재갑 인간 4-1비비 분자에 대한 인간화 항체 및 이를 포함하는 약학조성물
US6339062B1 (en) 1998-11-23 2002-01-15 Inkine Pharmaceutical Company, Inc. Retroinverso polypeptides that mimic or inhibit thrombospondin activity
EP1208219A1 (fr) 1999-04-08 2002-05-29 Pavel Sergeev Synthese de composes biologiquement actifs dans des cellules
US6159443A (en) 1999-04-29 2000-12-12 Vanderbilt University X-ray guided drug delivery
AUPQ014699A0 (en) 1999-05-04 1999-05-27 Access Pharmaceuticals Australia Pty Limited Amplification of folate-mediated targeting to tumor cells using nanoparticles
AUPQ014799A0 (en) 1999-05-04 1999-05-27 Access Pharmaceuticals Australia Pty Limited Amplification of folate-mediated targeting to tumor cells using polymers
WO2002032955A1 (fr) 2000-10-18 2002-04-25 The Government Of The United States Of America, As Represented By The Secretary Of The Department Of Health And Human Services. Gene humain indispensable a la fertilite
CA2427802A1 (fr) 2000-11-03 2002-05-10 Dana-Farber Cancer Institute Procedes et compositions pour le diagnostic des sensibilites aux cancers et mecanismes de reparation d'adn defectueux et traitement correspondant
US20050069538A1 (en) 2003-09-18 2005-03-31 Gregorio Aversa Therapeutic binding molecules
GB0110430D0 (en) 2001-04-27 2001-06-20 Medical Res Council Protein variants and uses thereof
US20110045005A1 (en) 2001-10-19 2011-02-24 Craig Crowley Compositions and methods for the treatment of tumor of hematopoietic origin
WO2003048327A2 (fr) 2001-12-03 2003-06-12 Abgenix, Inc. Anticorps anti-cd45rb s'utilisant dans le traitement de maladies auto-immunes et de rejet de greffon
US7183385B2 (en) 2002-02-20 2007-02-27 Cell Signaling Technology, Inc. Phospho-specific antibodies to Flt3 and uses thereof
US20030232369A1 (en) 2002-04-17 2003-12-18 Bushnell David A. Molecular structure of RNA polymerase II
US20030223989A1 (en) 2002-04-18 2003-12-04 Pluenneke John D. CD137 agonists to treat patients with IgE-mediated conditions
DE10219866A1 (de) 2002-05-03 2003-11-20 Isolde Riede-Kainrath Tumorprävention und Therapie durch Modifikation von "switch"-Genen oder RNA-Polymerase II-Aktivität
PL375144A1 (en) 2002-07-30 2005-11-28 Bristol-Myers Squibb Company Humanized antibodies against human 4-1bb
AU2002953073A0 (en) 2002-11-21 2003-01-16 Access Pharmaceuticals Australia Pty Limited Amplification of biotin-mediated targeting
US20060121030A1 (en) 2002-12-16 2006-06-08 Herbert Schwarz Use of cd 137 antagonists for the treatment of tumors
KR100500283B1 (ko) * 2003-03-25 2005-07-11 이뮤노믹스 주식회사 인간 4-1비비 분자에 대한 인간화 모노클로날 폴리펩티드 및 이를 포함하는 약학 조성물
US7288638B2 (en) 2003-10-10 2007-10-30 Bristol-Myers Squibb Company Fully human antibodies against human 4-1BB
CA2556752C (fr) 2004-02-23 2016-02-02 Genentech, Inc. Liants et conjugues heterocycliques auto-immolateurs
US20060014197A1 (en) 2004-07-15 2006-01-19 Wisconsin Alumni Research Foundation In vivo screening methods for identifying inhibitors of RNA polymerases
WO2006020145A2 (fr) 2004-07-19 2006-02-23 The Johns Hopkins University Inhibiteurs de flt3 a des fins d'immunodepression
EP1661584A1 (fr) 2004-11-26 2006-05-31 Heinz Dr. Faulstich Application de conjuguées d' amatoxines et de phallotoxines avec des macromolécules pour la thérapie du cancer et de l'Inflammation
US7947839B2 (en) 2004-12-01 2011-05-24 Genentech, Inc. Heterocyclic-substituted bis-1,8 naphthalimide compounds, antibody drug conjugates, and methods of use
US20080019905A9 (en) 2005-02-18 2008-01-24 Strome Scott E Method of using an anti-CD137 antibody as an agent for radioimmunotherapy or radioimmunodetection
US20060182744A1 (en) 2005-02-15 2006-08-17 Strome Scott E Anti-CD137 antibody as an agent in the treatment of cancer and glycosylation variants thereof
KR100694508B1 (ko) 2005-05-24 2007-03-13 울산대학교 산학협력단 Ｈｂｂｋ４항체를 포함하는 암 질환 치료용 약학조성물및 이를 이용한 암의 면역치료 방법
EP1986689A4 (fr) 2006-01-27 2009-09-02 Cellerant Therapeutics Inc Compositions et methodes de traitement de troubles proliferatifs hematologiques
US20090220529A1 (en) 2006-03-10 2009-09-03 Diatos, S.A. Anticancer Drugs Conjugated to Antibody via an Enzyme Cleavable Linker
TWI395754B (zh) 2006-04-24 2013-05-11 Amgen Inc 人類化之ｃ-ｋｉｔ抗體
ES2371085T3 (es) 2006-05-27 2011-12-27 Faulstich, Heinz, Dr. Utilización de conjugados de amatoxinas o falotoxinas con macromoléculas para la terapia tumoral y de la inflamación.
PL2032606T3 (pl) 2006-05-30 2014-04-30 Genentech Inc Przeciwciała i immunokoniugaty oraz ich zastosowania
CN103694349A (zh) * 2006-09-08 2014-04-02 米迪缪尼有限公司 人源化抗cd19抗体及其在治疗癌症、移植病和自身免疫病中的应用
US20120269774A1 (en) 2006-09-21 2012-10-25 Medistem Laboratories, Inc Allogeneic stem cell transplants in non-conditioned recipients
ES2642205T5 (en) 2006-11-03 2025-11-03 Univ Leland Stanford Junior Selective immunodepletion of endogenous stem cell niche for engraftment
EP2099823B2 (fr) 2006-12-01 2022-02-09 Seagen Inc. Agents se liantà des cibles variables et utilisations de ceux-ci
US20100093008A1 (en) 2007-03-02 2010-04-15 Cell Signaling Technology, Inc. Phospho-specific antibodies to flt3 (tyr969) and uses thereof
KR20080107050A (ko) 2007-06-05 2008-12-10 울산대학교 산학협력단 항-ｃｄ１３７ 단일클론 항체를 포함하는 만성이식편대숙주 질환의 예방 또는 치료용 약학적 조성물
CN101784565B (zh) 2007-06-25 2014-12-10 恩多塞特公司 含有亲水性间隔区接头的共轭物
US9518097B2 (en) 2007-11-09 2016-12-13 Board Of Trustees Of Michigan State University Identification and use of genes encoding amatoxin and phallotoxin
EP2279003A4 (fr) 2008-05-01 2013-04-03 Gtc Biotherapeutics Inc Anticorps anti-cd137 en tant qu'agent dans le traitement d'états inflammatoires
AR071891A1 (es) 2008-05-30 2010-07-21 Imclone Llc Anticuerpos humanos anti-flt3 (receptor tirosina cinasa 3 tipo fms humano)
AU2010234335A1 (en) * 2009-04-08 2011-10-13 Deutsches Krebsforschungszentrum Amatoxin-armed target-binding moieties for the treatment of cancer
SMT202000263T1 (it) * 2009-04-08 2020-07-08 Deutsches Krebsforsch Componenti terapeutici di legame alla superficie cellulare armati di amatossina destinati alla terapia contro i tumori
WO2010132389A2 (fr) 2009-05-14 2010-11-18 University Of Maryland, Baltimore Procédés de traitement de cancers et de maladies associées à l'expression de 4-1bb (cd137)
EP2266964B1 (fr) * 2009-06-22 2013-01-09 KTB Tumorforschungsgesellschaft mbH Unités de déclencheur d'acide labile
US8518405B2 (en) 2009-10-08 2013-08-27 The University Of North Carolina At Charlotte Tumor specific antibodies and uses therefor
SI2516468T1 (sl) 2009-12-23 2016-06-30 Synimmune Gmbh Protitelesa proti flt3 in postopki uporabe istih
HUE045270T2 (hu) 2010-01-05 2019-12-30 Inst Nat Sante Rech Med FLT3 receptor anatgonisták fájdalom rendellenességek kezelésére
KR20110085038A (ko) * 2010-01-19 2011-07-27 울산대학교 산학협력단 항 ｃｄ137-항체 및 독소 결합물을 이용한 ｃｄ137 양성세포의 제거방법
WO2011130613A1 (fr) 2010-04-15 2011-10-20 Seattle Genetics, Inc. Conjugués de pyrrolobenzodiazapine ciblés
EP2603231B1 (fr) 2010-07-13 2021-12-29 Rhode Island Board Of Governors For Higher Education Compositions comprenant un polypeptide d'insertion membranaire sensible au pH.
BR112013005699B1 (pt) 2010-09-09 2021-08-17 Pfizer Inc Anticorpo isolado ou porção de ligação ao antígeno do mesmo que se liga ao 4-1bb humano, combinação, usos dos mesmos, bem como composição farmacêutica, molécula de ácido nucleico isolada e vetor
ES2402254T3 (es) 2010-09-30 2013-04-30 Heidelberg Pharma Ag Conjugados de amatoxinas con ligadores mejorados
EP2656079A2 (fr) 2010-12-20 2013-10-30 Universiteit Gent Structure cristalline du complexe ligand-récepteur flt3
AR085091A1 (es) 2011-01-26 2013-09-11 Kolltan Pharmaceuticals Inc Anticuerpos anti-kit y sus usos
EP2497499A1 (fr) 2011-03-10 2012-09-12 Heidelberg Pharma GmbH Conjugués d'amatoxine avec liens améliorés
AU2012230780B2 (en) 2011-03-23 2016-10-27 Fred Hutchinson Cancer Center Method and compositions for cellular immunotherapy
WO2012145112A2 (fr) * 2011-04-18 2012-10-26 Immunogen, Inc. Nouveaux dérivés de maytansinoïdes comprenant un lieur sulfoxyde
TR201905909T4 (tr) 2011-04-19 2019-05-21 Pfizer Kanser tedavisi için anti-4-1bb antikorlarının ve adcc indükleyici antikorların kombinasyonları.
HRP20191586T1 (hr) 2011-05-08 2019-12-13 Legochem Biosciences Inc Konjugati agensa aktivni na proteine i postupak pripreme istih
AR086044A1 (es) 2011-05-12 2013-11-13 Imclone Llc Anticuerpos que se unen especificamente a un dominio extracelular de c-kit y usos de los mismos
WO2012177788A1 (fr) 2011-06-20 2012-12-27 La Jolla Institute For Allergy And Immunology Modulateurs de 4-1bb et réponses immunitaires
CN103998449A (zh) 2011-10-14 2014-08-20 斯皮罗根有限公司 吡咯并苯并二氮杂卓
BR122021017842B1 (pt) 2011-10-14 2021-12-14 Medimmune Limited Compostos pirrolobenzodiazepinas e conjugados alvos
ES2864323T3 (es) 2011-12-22 2021-10-13 Yeda Res & Dev Una terapia de combinación para un injerto estable y a largo plazo
CA3111357A1 (fr) 2011-12-23 2013-06-27 Pfizer Inc. Regions constantes d'anticorps modifies pour conjugaison specifique a un site, et leurs procedes et utilisations
US9504756B2 (en) 2012-05-15 2016-11-29 Seattle Genetics, Inc. Self-stabilizing linker conjugates
EP2849797B1 (fr) 2012-05-15 2019-12-18 Concortis Biosystems, Corp Conjugués médicamenteux, procédés de conjugaison et utilisations de ceux-ci
WO2013192546A1 (fr) 2012-06-22 2013-12-27 Cytomx Therapeutics, Inc. Anticorps activables ayant des fragments stériques ne se liant pas et leurs procédés d'utilisation
EP2684865A1 (fr) 2012-07-13 2014-01-15 Heidelberg Pharma GmbH Procédés de synthèse de bloc de construction dýamatoxine et amatoxine
EP3381943B1 (fr) 2012-07-25 2022-03-16 Celldex Therapeutics, Inc. Anticorps anti-kit et leurs utilisations
US20150218220A1 (en) 2012-09-12 2015-08-06 Brian Alan MENDELSOHN Amatoxin derivatives and cell-permeable conjugates thereof as inhibitors of rna polymerase
CA2885796C (fr) 2012-09-24 2022-05-03 Allozyne, Inc. Lignee cellulaire
GB201217296D0 (en) 2012-09-27 2012-11-14 Alta Innovations Ltd Method of treatment and/or prevention
CN104869998A (zh) 2012-10-16 2015-08-26 恩多塞特公司 含有非天然氨基酸的药物递送缀合物以及其使用方法
SG11201508027PA (en) 2013-02-28 2015-11-27 Harvard College Methods and compositions for mobilizing stem cells
EP2774624A1 (fr) 2013-03-04 2014-09-10 Heidelberg Pharma GmbH Dérivés d'amatoxine
MX368665B (es) 2013-03-15 2019-10-10 Abbvie Biotherapeutics Inc Variantes de fc.
US9498540B2 (en) 2013-03-15 2016-11-22 Novartis Ag Cell proliferation inhibitors and conjugates thereof
SG11201506395RA (en) 2013-03-15 2015-09-29 Novartis Ag Antibody drug conjugates
EP2777714A1 (fr) 2013-03-15 2014-09-17 NBE-Therapeutics LLC Procédé de production d'un conjugué de ligand immunologique/charge utile à l'aide d'une enzyme transpeptidase spécifique pour une séquence
MD4633B1 (ro) * 2013-03-18 2019-06-30 Biocerox Products B.V. Anticorpi umanizaţi anti-CD134 (OX40) şi utilizarea acestora
US9803002B2 (en) 2013-05-31 2017-10-31 Genentench, Inc. Anti-wall teichoic antibodies and conjugates
WO2014197854A1 (fr) 2013-06-06 2014-12-11 Igenica Biotherapeutics, Inc. Nouveaux lieurs pour conjugués anticorps-médicament et composés connexes, compositions, et procédés d'utilisation
KR101641206B1 (ko) 2013-06-24 2016-07-22 에이비엘바이오 주식회사 안정성이 개선된 항체-약물 결합체 및 이의 용도
WO2015006554A1 (fr) 2013-07-10 2015-01-15 The Regents Of The University Of Michigan Anticorps thérapeutiques et utilisations de ceux-ci
FR3008408B1 (fr) 2013-07-11 2018-03-09 Mc Saf Nouveaux conjugues anticorps-medicament et leur utilisation en therapie
JP6439690B2 (ja) 2013-07-12 2018-12-19 石原産業株式会社 細胞への遺伝子導入用組成物
WO2015067667A1 (fr) 2013-11-05 2015-05-14 INSERM (Institut National de la Santé et de la Recherche Médicale) Anticorps anti-kit neutralisants humains et leurs utilisations
KR20150055655A (ko) 2013-11-13 2015-05-22 삼성디스플레이 주식회사 기판 세정 장치
AU2015229463A1 (en) 2014-03-12 2016-09-15 Novartis Ag Specific sites for modifying antibodies to make immunoconjugates
CA2950155C (fr) 2014-06-02 2021-11-23 Regeneron Pharmaceuticals, Inc. Conjugues de molecules biologiquement actives, reactifs et methodes de fabrication, et utilisations therapeutiques
DK3160513T3 (da) 2014-06-30 2020-04-06 Glykos Finland Oy Saccharidderivat af en toksisk payload og antistofkonjugater deraf
US20170226209A1 (en) 2014-08-01 2017-08-10 INSERM (Institut National de la Santé et de la Recherche Médicale) An anti-cd45rc antibody for use as drug
PL3656869T5 (pl) 2014-08-26 2025-06-09 The Board Of Trustees Of The Leland Stanford Junior University Wszczepienie komórek macierzystych z kombinacją środka, który celuje w komórki macierzyste i modulowanie sygnałowania immunoregulatorowego
WO2016036334A1 (fr) 2014-09-03 2016-03-10 Şahi̇n Yücel Procédés voltamétriques pour la détermination d'alpha-amanitine et de phalloïdine
GB201416960D0 (en) * 2014-09-25 2014-11-12 Antikor Biopharma Ltd Biological materials and uses thereof
AU2015324924B2 (en) 2014-10-01 2021-07-01 Medimmune, Llc Method of conjugating a polypeptide
WO2016064749A2 (fr) 2014-10-20 2016-04-28 Igenica Biotherapeutics, Inc. Nouveaux conjugués anticorps-médicament et composés, compositions et procédés d'utilisation s'y rapportant
EP3215519A1 (fr) * 2014-11-06 2017-09-13 Novartis AG Dérivés d'amatoxine et leurs conjugués comme inhibiteurs de l'arn polymérase
JP2018500049A (ja) 2014-11-11 2018-01-11 アムニクス オペレーティング インコーポレイテッド ターゲティングｘｔｅｎコンジュゲート組成物およびそれを作製する方法
EP3026060A1 (fr) 2014-11-26 2016-06-01 Miltenyi Biotec GmbH Anticorps humanisé, ou fragment de celui-ci spécifique pour CD45R0
BR112017013189B1 (pt) 2015-01-08 2024-03-05 Genmab A/S Agentes agonísticos de ligação ao receptor de tnf
US20160220687A1 (en) 2015-02-02 2016-08-04 National Guard Health Affairs Metalloproteinase-cleavable alpha-amanitin-dendrimer conjugates and method of treating cancer
EP3259285A2 (fr) 2015-02-16 2017-12-27 Lonza Ltd Anticorps
PT3265565T (pt) 2015-03-04 2020-11-17 Univ Texas Métodos de tratamento de cancro albergando perda hemizigótica de tp53
HRP20240075T1 (hr) 2015-03-09 2024-03-29 Heidelberg Pharma Research Gmbh Konjugati amatoksin-protutijela
CA2978631C (fr) 2015-03-09 2023-06-27 Agensys, Inc. Conjugues anticorps-medicament (cam) se liant aux proteines flt3
US20180318285A1 (en) 2015-03-10 2018-11-08 President And Fellows Of Harvard College Methods for treatment of autism spectrum disorders
IL287952B2 (en) 2015-04-06 2024-11-01 Harvard College Compositions and methods for non-myeloablative conditioning
WO2016164745A1 (fr) 2015-04-10 2016-10-13 The Methodist Hospital System Conjugués de médicament-ligand cd117 pour traitement ciblé contre le cancer
US20180110871A1 (en) 2015-04-17 2018-04-26 Endocyte, Inc. Dual disulfide drug conjugates
RU2017138083A (ru) 2015-05-18 2019-06-18 Универсидади Ду Порту Применение полимиксина в качестве антидота при отравлениях аматоксинами
US10806808B2 (en) 2015-05-22 2020-10-20 Memorial Sloan Kettering Cancer Center Systems and methods for determining optimum patient-specific antibody dose for tumor targeting
AU2016279051B2 (en) 2015-06-19 2021-02-18 Ladrx Corporation Delivery systems for controlled drug release
WO2017004127A1 (fr) 2015-06-29 2017-01-05 The General Hospital Corporation Inhibition de l'embigine pour promouvoir l'expansion de cellules souches et progénitrices hématopoïétiques
JP2018524373A (ja) * 2015-07-15 2018-08-30 ザイムワークス，インコーポレイテッド 薬物がコンジュゲートされた二重特異性抗原結合コンストラクト
US20180312592A1 (en) 2015-07-16 2018-11-01 Cellerant Therapeutics, Inc. Cysteine-substituted immunoglobulins
HK1254976A1 (zh) 2015-07-31 2019-08-02 University Of Florida Research Foundation, Inc. 造血干细胞和抗癌免疫检查点抑制剂的组合疗法
WO2017051249A1 (fr) 2015-09-25 2017-03-30 Legochem Biosciences, Inc. Compositions et méthodes associées à des conjugués anticorps anti-cd19-médicaments
JP6621919B2 (ja) 2015-10-16 2019-12-18 ジェネンテック， インコーポレイテッド 束縛ジスルフィド薬物コンジュゲート
CA3002588C (fr) 2015-10-23 2021-11-23 Apogenix Ag Proteines agonistes du recepteur cd137 a chaine unique
AU2016360828B2 (en) 2015-11-27 2021-06-24 Heidelberg Pharma Research Gmbh Derivatives of gamma-amanitin
US11129910B2 (en) * 2016-02-04 2021-09-28 Hangzhou Dac Biotech Co., Ltd. Specific conjugation linkers, specific immunoconjugates thereof, methods of making and uses such conjugates thereof
EP3222292A1 (fr) 2016-03-03 2017-09-27 Heidelberg Pharma GmbH Conjugués d'amanitine
JP7295640B2 (ja) 2016-04-20 2023-06-21 ハンジョウ ディーエーシー バイオテック シーオー．，エルティディ． アマニタ毒素の誘導体及びそれらと細胞結合分子との共役体
US10464969B2 (en) 2016-05-05 2019-11-05 Novartis Ag Amatoxin derivatives and conjugates thereof as inhibitors of RNA polymerase
EP3471771A4 (fr) 2016-05-31 2020-04-15 Sorrento Therapeutics, Inc. Conjugués anticorps-médicaments ayant des dérivés d'amatoxine en tant que médicament
JP7062647B2 (ja) 2016-06-17 2022-05-06 マジェンタ セラピューティクス インコーポレイテッド Ｃｄ１１７＋細胞を枯渇させるための組成物及び方法
ES3000471T3 (en) 2016-12-23 2025-02-28 Heidelberg Pharma Res Gmbh Amanitin antibody conjugates
WO2018134787A2 (fr) * 2017-01-20 2018-07-26 Magenta Therapeutics, Inc. Compositions et procédés pour la déplétion des cellules cd137+
US11420971B2 (en) 2017-08-07 2022-08-23 Heidelberg Pharma Research Gmbh Method for synthesizing amanitins

Also Published As

Publication number Publication date
KR20240161216A (ko) 2024-11-12
US10576161B2 (en) 2020-03-03
CA3049501A1 (fr) 2018-07-26
BR112019014991A2 (pt) 2020-04-07
TW201833134A (zh) 2018-09-16
IL268058B1 (en) 2023-05-01
US20200289664A1 (en) 2020-09-17
JP7256744B2 (ja) 2023-04-12
EP3571230A4 (fr) 2020-12-16
MX2022011546A (es) 2022-10-18
WO2018134787A2 (fr) 2018-07-26
CN110461876B (zh) 2024-05-17
SG10202102897PA (en) 2021-04-29
CN110461876A (zh) 2019-11-15
US20180289832A1 (en) 2018-10-11
MX395639B (es) 2025-03-25
EP3571230A2 (fr) 2019-11-27
MX2019008205A (es) 2020-01-23
IL268058B2 (en) 2023-09-01
IL268058A (en) 2019-09-26
KR102725761B1 (ko) 2024-11-04
AU2018209452B2 (en) 2024-11-07
JP2023093500A (ja) 2023-07-04
JP2020506176A (ja) 2020-02-27
AU2018209452A1 (en) 2019-07-18
SG11201906319XA (en) 2019-08-27
TWI825007B (zh) 2023-12-11
KR20190107097A (ko) 2019-09-18
US10434185B2 (en) 2019-10-08
WO2018134787A3 (fr) 2018-10-04
US20190076548A1 (en) 2019-03-14

Similar Documents

Publication Publication Date Title
MA47331A (fr) Compositions et procédés pour la déplétion des cellules cd137+
EP3503901A4 (fr) Procédés et compositions pour cellules de moelle épinière
EP3472178A4 (fr) Compositions et procédés pour la déplétion des cellules cd117+
EP3429603A4 (fr) Procédés et compositions concernant l'expansion de cellules souches hématopoïétiques
EP3371301A4 (fr) Procédés et compositions pour induire la différenciation de cellules hématopoïétiques
IL311608B1 (en) Compositions and methods for selective removal and replacement of hematopoietic stem cells
EP3717022A4 (fr) Compositions et procédés pour la déplétion des cellules cd5+
EP3383411A4 (fr) Procédés et compositions se rapportant à des chondrisomes provenant de cellules cultivées
MA45407A (fr) Compositions et méthodes de déplétion de cellules
SG11202104524YA (en) Compositions and methods for t cell engineering
EP3793579A4 (fr) Procédés et compositions pour générer des cellules de lignée endodermique et des cellules bêta et utilisations associées
IL269334A (en) Improved t cell compositions and methods
MA50858A (fr) Procédés, compositions et composants pour l'édition crispr-cas9 de tgfbr2 dans des cellules t pour l'immunothérapie
EP3370741A4 (fr) Procédés et compositions pour l'édition de gènes dans des cellules souches hématopoïétiques
MA49979A (fr) Procédés de production de compositions de cellules génétiquement modifiées et compositions associées
MA49981A (fr) Procédés et compositions de préparation de cellules génétiquement modifiées
PL3194570T3 (pl) Sposoby i kompozycje do inżynierii genomowej w której pośredniczy nukleaza i korekty hematopoetycznych komórek macierzystych
EP3472307A4 (fr) Procédés et compositions de potentialisation de thérapies de cellules souches
EP3008170A4 (fr) Cellules dérivées de cellules souches et compositions et procédés pour générer ces cellules
MA46959A (fr) Cellules b modifiées et compositions et méthodes associées
EP2970890A4 (fr) Compositions et procédés pour le développement et la culture de cellules souches épithéliales
EP3371314A4 (fr) Ingénierie génomique de cellules pluripotentes
MA43943A (fr) Compositions et procédés pour traiter des patients avec des cellules mutantes rtk
EP2978419A4 (fr) Compositions pour améliorer la viabilité de cellules et procédés pour leur utilisation
EP3347449A4 (fr) Procédés d'expansion de cellules et compositions thérapeutiques